Andere Sprachen Salarius Pharmaceuticals, Inc.

Aktien

A40EWG

US79400X4043

SLRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 28.06.2024			% 5 Tage	% 1. Jan.
2.38 ^USD	-2.86%		-5.56%	-54.23%

17.06.	Klinische Daten zu Salarius Pharmaceuticals? Seclidemstat bei Patienten mit Mds und Cmml werden auf der Jahrestagung 2024 der European Hematology Association vorgestellt	CI
13.05.	Salarius Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting	17.06.
Clinical Data on Salarius Pharmaceuticals? Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting	17.06.
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split	12.06.
Salarius: Q1 Earnings Snapshot	13.05.
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	25.03.
Top Premarket Gainers	25.03.
North American Morning Briefing : Tech in Focus on -2-	25.03.
Salarius: Q4 Earnings Snapshot	22.03.
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.03.
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	22.03.
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22.02.
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22.02.
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders	16.01.
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center	03.01.
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment	03.01.
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20.12.
North American Morning Briefing : Stock Futures -2-	16.11.
Salarius: Q3 Earnings Snapshot	10.11.
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Salarius Pharmaceuticals, Inc.

Aktien

A40EWG

US79400X4043

SLRX

Andere Sprachen

Filter